Last reviewed · How we verify
Kunming Baker Norton Pharmaceutical Sales Co., Ltd. — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| DICL-SR | DICL-SR | marketed | NSAID (nonsteroidal anti-inflammatory drug) | COX-1 and COX-2 | Rheumatology / Pain Management |
Therapeutic area mix
- Rheumatology / Pain Management · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Depomed · 1 shared drug class
- Dong-A ST Co., Ltd. · 1 shared drug class
- Handok Inc. · 1 shared drug class
- Imprimis Pharmaceuticals, Inc. · 1 shared drug class
- LEO Pharma · 1 shared drug class
- Novartis · 1 shared drug class
- Pfizer · 1 shared drug class
- University of South Alabama · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Kunming Baker Norton Pharmaceutical Sales Co., Ltd.:
- Kunming Baker Norton Pharmaceutical Sales Co., Ltd. pipeline updates — RSS
- Kunming Baker Norton Pharmaceutical Sales Co., Ltd. pipeline updates — Atom
- Kunming Baker Norton Pharmaceutical Sales Co., Ltd. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Kunming Baker Norton Pharmaceutical Sales Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/kunming-baker-norton-pharmaceutical-sales-co-ltd. Accessed 2026-05-18.